Clinical trial
Idarubicin Based Combined Modality Therapy in Primary CNS Lymphoma
NCT00193973 · Trans Tasman Radiation Oncology Group, Other · Completed
Key facts
| NCT number | NCT00193973 |
|---|---|
| Title | Idarubicin Based Combined Modality Therapy in Primary CNS Lymphoma |
| Official title | A Phase 2 Study of Idarubicin Based Combined Modality Therapy in Primary Central Nervous System Lymphoma |
| Lead sponsor | Trans Tasman Radiation Oncology Group, Other |
| Collaborators | Australasian Leukaemia and Lymphoma Group |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Primary Central Nervous System Lymphoma |
| Intervention type | Drug, Radiation |
| Interventions | Idarubicin, Methotrexate, Filgrastim, intrathecal Ara-C, Radiation Therapy |
| Enrollment | 20 |
| Start date | Jul 1, 2001 |
| Primary completion | Jul 1, 2008 |
| Completion | Aug 1, 2013 |
| First posted | Sep 19, 2005 |
| Last update posted | Feb 17, 2017 |
| Countries | Australia, New Zealand |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: